Results 11 to 20 of about 46,326 (218)

Nrf2: a dark horse in doxorubicin-induced cardiotoxicity

Cell Death Discovery, 2023
Being a broad-spectrum anticancer drug, doxorubicin is indispensable for clinical treatment. Unexpectedly, its cardiotoxic side effects have proven to be a formidable obstacle.
Xiaopeng Zhao, Zheng Tian, Mingli Sun, Dan Dong   +3 more
doaj   +1 more source

Prognostic Factors for Cardiotoxicity among Children with Cancer: Definition, Causes, and Diagnosis with Omics Technologies

Diagnostics, 2023
Improvements in the treatment of childhood cancer have considerably enhanced survival rates over the last decades to over 80% as of today. However, this great achievement has been accompanied by the occurrence of several early and long-term treatment ...
Kondylia Antoniadi, Nikolaos Thomaidis, Petros Nihoyannopoulos, Konstantinos Toutouzas, Evangelos Gikas, Charikleia Kelaidi, Sophia Polychronopoulou   +6 more
doaj   +1 more source

Early detection of anthracycline‐ and trastuzumab‐induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters

ESC Heart Failure, 2022
Aims To evaluate echocardiographic and biomarker changes during chemotherapy, assess their ability to early detect and predict cardiotoxicity and to define the best time for their evaluation. Methods and results Seventy‐two women with breast cancer (52 ± 
Belén Díaz‐Antón, Rodrigo Madurga, Blanca Zorita, Samantha Wasniewski, Andrea Moreno‐Arciniegas, Beatriz López‐Melgar, Natalia Ramírez Merino, Roberto Martín‐Asenjo, Patricia Barrio, Maximiliano German Amado Escañuela, Jorge Solís, Francisco Javier Parra Jiménez, Eva Ciruelos, José María Castellano, Leticia Fernández‐Friera   +14 more
doaj   +1 more source

Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis

Frontiers in Immunology, 2022
Immune checkpoint inhibitors (ICIs) in combination withother anti-cancer treatments have been approved for a variety of cancers. While the difference in the incidence of cardiovascular adverse events has not been fully investigated.
Maobai Liu, Maobai Liu, Xitong Cheng, Xitong Cheng, Ruping Ni, Ruping Ni, Bin Zheng, Bin Zheng, Shunmin Huang, Shunmin Huang, Jing Yang, Jing Yang   +11 more
doaj   +1 more source

Prevalence and Risk Factors of Cardiotoxicity in Elderly Cancer Patients [PDF]

The Egyptian Journal of Geriatrics and Gerontology, 2023
Background: Cancer and heart disease are the leading causes of death in older adults. Cardiotoxicity of anticancer agents may lead to under-treatment of elderly patients, resulting in suboptimal outcomes.Aim: To determine the prevalence and risk factors ...
Maha A.Ali, Hala Samir Sweed, Mohamed Ahmed Alsadany, Ghada Kazamel, Mohamed F.Tolba   +4 more
doaj   +1 more source

Risk factors of osimertinib-related cardiotoxicity in non-small cell lung cancer

Frontiers in Oncology
ObjectiveTo investigate the risk factors associated with cardiotoxicity in patients with non-small cell lung cancer (NSCLC) treated with osimertinib.MethodsA total of 268 patients with NSCLC treated with osimertinib in our hospital from June 2019 to ...
Yunlong Wang, Xuan Deng, Qinggui Qiu, Mengchao Wan   +3 more
doaj   +1 more source

Paclitaxel-induced Cardiotoxicity: Mechanisms, Molecular Insights, and Clinical Implications [PDF]

Archives of Pharmaceutical Sciences Ain Shams University
Paclitaxel is a well-known chemotherapeutic agent used to treat various cancers, including breast, lung, and pancreatic cancers. However, its effectiveness is limited by significant adverse effects, including neurotoxicity, nephrotoxicity, hepatotoxicity,
El-Nagar, Yasmine M., George, Mina Y., El Wakeel, Sara, Elsherbiny, Doaa A.   +3 more
doaj   +1 more source

Risk Compounds, Preclinical Toxicity Evaluation, and Potential Mechanisms of Chinese Materia Medica–Induced Cardiotoxicity

Frontiers in Pharmacology, 2021
Chinese materia medica (CMM) has been applied for the prevention and treatment of diseases for thousands of years. However, arrhythmia, myocardial ischemia, heart failure, and other cardiac adverse reactions during CMM application were gradually reported.
Jie Zhou, Jie Zhou, Jie Zhou, Fu Peng, Xiaoyu Cao, Xiaoyu Cao, Xiaofang Xie, Xiaofang Xie, Dayi Chen, Lian Yang, Chaolong Rao, Cheng Peng, Cheng Peng, Xiaoqi Pan, Xiaoqi Pan   +14 more
doaj   +1 more source

Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility

Acta Oncologica
Background: BRAF/MEK inhibitors (BRAFi/MEKi) improve outcome in patients with BRAF-mutated metastatic melanoma but are associated with cardiotoxicity, leading to a decline in left ventricular ejection fraction (LVEF).
Jonas K. Oddershede, Ida K. Meklenborg, Lars Bastholt, Louise M. Guldbrandt, Henrik Schmidt, Rasmus B. Friis   +5 more
doaj   +1 more source

Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs

Frontiers in Oncology
Breast cancer is a major health challenge for women worldwide, and human epidermal growth factor receptor 2 (HER-2)-positive breast cancers have a relatively high incidence and are highly aggressive.
Xiang Zhang, Yulian Yin, Qiuting Yu, Xinlin Chen, Yiqin Cheng   +4 more
doaj   +1 more source